Otonomy begins OTO-313 Phase 1/2 clinical study for tinnitus patients
Category: #health  By Mateen Dalal  Date: 2019-04-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Otonomy begins OTO-313 Phase 1/2 clinical study for tinnitus patients

Results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development

Biopharmaceutical firm Otonomy, Inc., has reportedly initiated the Phase 1/2 clinical trial of OTO-313 in patients suffering from tinnitus. OTO-313, apparently, is a sustained-exposure formulation of gacyclidine, the NMDA receptor antagonist.

The Phase 1/2 study, which is double-blind, randomized and placebo-controlled, would consist of an initial safety cohort to be followed by an exploratory study of efficacy, enrolling nearly 50 patients having subjective tinnitus, Otonomy confirmed.

Otologist and Neurotologist at the Ear Medical Group in San Antonio and a University of Texas Health Science Center clinical professor, Susan Marenda King, M.D., said that tinnitus has become a common issue that affects millions of people.

The disorder can lead to constant annoyance which negatively impacts the quality of life of a person, by disrupting their concentration and the ability to enjoy leisurely activities or obtain sufficient sleep, Dr. Susan added. She also mentioned that presently, there is no drug therapy for treating these patients.

President and CEO of Otonomy, David A. Weber, Ph.D., stated that this trial of OTO-313 would be evaluating its potential as a therapy for patients with tinnitus. He informed that results from the trial are expected in the first half of 2020 and the information would be used to design and plan any further clinical development.

Supposedly, a Phase 1 clinical safety trial had been completed earlier for an initial formulation of gacyclidine, where no safety concerns were observed. OTO-313 is considered as an enhanced formulation of gacyclidine and a single intratympanic injection is to be used for its administration.

For the uninitiated, tinnitus is the medical term used when a person experiences the perception of noise even when there is no sound. Patients often described it as a ringing in the ear, but it can also sound like clicking, roaring, buzzing or hissing. Estimates show that nearly 10% of U.S. adults are living with this condition.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...